e-med
[Top] [All Lists]

[e-med] WHO Pharmaceuticals Newsletter No. 2, 2018

WHO Pharmaceuticals Newsletter No. 2, 2018
Authors: Quality Assurance and Safety
Editors: Noha Iessa, Takahiro Goto
Number of pages: 26
Publication date: April 2018
Languages: English

Le bulletin d'information pharmaceutique de l'OMS vous fournit (en anglais) les 
dernières informations sur la sécurité des médicaments et les actions en 
justice entreprises par les autorités de réglementation dans le monde entier. 
Il fournit également des signaux basés sur les informations tirées des rapports 
individuels de sécurité des cas (ICSR) disponibles dans la base de données 
mondiale ICSR de l'OMS, VigiBase®.

WHO Pharmaceuticals Newsletter - No. 2, 2018 - pdf, 613Kb
http://www.who.int/medicines/publications/PharmaNewsletter2_18/en/

Sommaire

Regulatory Matters
Antihistamines (first generation, oral sedating) 
........................................ 5
Clarithromycin 
.....................................................................................
 5
Clopidogrel and selexipag interaction 
...................................................... 5
Daclizumab beta 
..................................................................................
 5
Dipeptidylpeptidase-4 inhibitors 
............................................................. 6
Efavirenz.............................................................................................
 6
Flupirtine 
............................................................................................
 6
Gadolinium-containing contrast agents 
................................................... 7
Hydroxyethyl-starch solution 
................................................................. 7
Iohexol, Iomeprol 
................................................................................
 7
Kampo medicines containing Gardenia fruit 
............................................. 8
Miconazole and warfarin interaction 
........................................................ 8
Mycophenolate mofetil, mycophenolic acid 
.............................................. 8
Radium-223 dichloride 
.......................................................................... 8
Retinoids 
.............................................................................................
 9
Sterile talc 
..........................................................................................
 9
Tolvaptan 
............................................................................................
 9

Safety of medicines
Artemisia annua extract in grape seed oil 
.............................................. 10
Aspirin in chloroform 
.......................................................................... 10
Clozapine 
..........................................................................................
 10
Dabigatran 
........................................................................................
 10
Direct-acting antivirals (DAAs) 
............................................................. 11
Eribulin 
.............................................................................................
 11
Idarucizumab 
....................................................................................
 11
Ruxolitinib 
.........................................................................................
 11
Sodium-glucose Cotransporter-2 (SGLT2) inhibitors 
............................... 12
Suvorexant 
.......................................................................................
 12
Ulipristal acetate 
................................................................................
 12
WHO Pharmaceuticals Newsletter No. 2, 2018 • 4

Signal
Artemether/Lumefantrine and Stevens-Johnson syndrome: a
recommendation for continued vigilance in malaria-endemic areas ........... 14
Quetiapine and valproic acid interactions: signal strengthening 
................ 19

Feature
Enhancing Pharmacovigilance in Low and Middle Income Countries using
Smart Safety Surveillance 
................................................................... 26

<Prev in Thread] Current Thread [Next in Thread>
  • [e-med] WHO Pharmaceuticals Newsletter No. 2, 2018, e-med <=